The use of sulfonylamido pyrimidines incorporating an unsaturated side chain as endothelin receptor antagonists
作者:Martin H Bolli、Christoph Boss、Martine Clozel、Walter Fischli、Patrick Hess、Thomas Weller
DOI:10.1016/s0960-894x(02)01084-3
日期:2003.3
A series of compounds structurally related to bosentan 1 featuring an unsaturatedsidechain at position 6 of the core pyrimidine have been studied for their potential to block the ET(A) and ET(B) receptor. Incorporation of a 2-butyne-1,4-diol linker bearing a pyridyl carbamoyl moiety led to in vitro highly potent endothelin receptor antagonists (e.g., 70 and 75). The propargyl derivative 26 significantly
The present invention relates to novel butyne diol derivatives of the general formula I and their use as active ingredients in the preparation of pharmaceutical compositions. The invention also concerns related aspects including processes for the preparation of the compounds, pharmaceutical compositions containing one or more compounds of the general formula I and especially their use as endothelin receptor antagonists.
Novel sulfamides and their use as endothelin receptor antagonists
申请人:——
公开号:US20040077670A1
公开(公告)日:2004-04-22
The invention relates to novel sulfamides and their use as active ingredients in the preparation of pharmaceutical compositions. The invention also concerns related aspects including processes for the preparation of the compounds, pharmaceutical compositions containing one or more of those compounds and especially their use as endothelin receptor antagonists.
[EN] NOVEL SULFAMIDES AND THEIR USE AS ENDOTHELIN RECEPTOR ANTAGONISTS<br/>[FR] NOUVEAUX SULFAMIDES ET LEUR UTILISATION COMME ANTAGONISTES DU RECEPTEUR DE L'ENDOTHELINE
申请人:ACTELION PHARMACEUTICALS LTD
公开号:WO2002053557A1
公开(公告)日:2002-07-11
The invention relates to novel sulfamides of general formula (I) and their use as active ingredients in the preparation of pharmaceutical compositions. The invention also concerns related aspects including processes for the preparation of the compounds, pharmaceutical compositions containing one or more of those compounds and especially their use as endothelin receptor antagonists.
The invention relates to novel sulfamides and their use as active ingredients in the preparation of pharmaceutical compositions. The invention also concerns related aspects including processes for the preparation of the compounds, pharmaceutical compositions containing one or more of those compounds and especially their use as endothelin receptor antagonists.